382 related articles for article (PubMed ID: 12969808)
1. Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2.
Golay J; Manganini M; Facchinetti V; Gramigna R; Broady R; Borleri G; Rambaldi A; Introna M
Haematologica; 2003 Sep; 88(9):1002-12. PubMed ID: 12969808
[TBL] [Abstract][Full Text] [Related]
2. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
3. Effect of alemtuzumab on neoplastic B cells.
Golay J; Manganini M; Rambaldi A; Introna M
Haematologica; 2004 Dec; 89(12):1476-83. PubMed ID: 15590398
[TBL] [Abstract][Full Text] [Related]
4. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
5. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells].
Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ
Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543
[TBL] [Abstract][Full Text] [Related]
6. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
7. [Interleukin-2 improves the antitumor activity of Rituximab in patients with B-cell lymphoma in vitro].
Zhang WX; Guo J; Lin BH; Meng SN; Wang XP; Xie Y; Zheng W; Zhang YT; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):41-4. PubMed ID: 17649726
[TBL] [Abstract][Full Text] [Related]
8. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
10. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
11. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J
J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
13. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines.
Flieger D; Renoth S; Beier I; Sauerbruch T; Schmidt-Wolf I
Cell Immunol; 2000 Aug; 204(1):55-63. PubMed ID: 11006018
[TBL] [Abstract][Full Text] [Related]
15. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
[TBL] [Abstract][Full Text] [Related]
16. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms.
Voso MT; Pantel G; Rutella S; Weis M; D'Alò F; Urbano R; Leone G; Haas R; Hohaus S
Haematologica; 2002 Sep; 87(9):918-25. PubMed ID: 12217803
[TBL] [Abstract][Full Text] [Related]
17. Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.
Pfeiffer M; Stanojevic S; Feuchtinger T; Greil J; Handgretinger R; Barbin K; Jung G; Martin D; Niethammer D; Lang P
Bone Marrow Transplant; 2005 Jul; 36(2):91-7. PubMed ID: 15908973
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression.
Moga E; Cantó E; Vidal S; Juarez C; Sierra J; Briones J
Exp Hematol; 2011 Nov; 39(11):1064-71. PubMed ID: 21864486
[TBL] [Abstract][Full Text] [Related]
19. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells.
Wulf GG; Boehnke A; Chapuy B; Glass B; Hemmerlein B; Schroers R; Brenner MK; Truemper L
Haematologica; 2006 Jul; 91(7):886-94. PubMed ID: 16818275
[TBL] [Abstract][Full Text] [Related]
20. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
